R&D News | pharmaphorum

News

Aptar buys digital health partner Healint

More evidence of consolidation in the digital health category has come with the news that Aptar has bought Singapore’s Healint, which develops patient support apps as well

News

RAPT hit by FDA clinical hold on eczema, asthma drug

RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma

News

AbbVie looks internally for its new CEO, naming COO Michael

The speculation over who will replace long-serving AbbVie chief executive Richard Gonzalez is over, as the company confirms that president and chief operating officer Robe

News

Prof Jean-Phillipe Vert, Owkin's chief R&D officer

Bioptimus born with $35m for a foundation model for biology

A team of scientists formerly working at Google DeepMind and Owkin have joined forces to create Bioptimus, a start-up that will apply generative artificial intelligence (G

News

Bayer takes novel deep vein thrombosis drug into phase 2

Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs.

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

Aptar buys digital health partner Healint

RAPT hit by FDA clinical hold on eczema, asthma drug

AbbVie looks internally for its new CEO, naming COO Michael

Bioptimus born with $35m for a foundation model for biology

Bayer takes novel deep vein thrombosis drug into phase 2

AZ, Daiichi eye December verdict for TROP2 ADC

NHS study will pick apart mental illness with data science

How to meet your physicians where they are online

News

Editor's Picks